Compare Corsair Gaming Inc (CRSR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corsair Gaming Inc vs Merck & Co., Inc. — how do they compare? Corsair Gaming Inc trades at $13.63 (market cap $1.42B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 247.4× Corsair Gaming Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Corsair Gaming Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and Merck & Co., Inc. for 98 Days on average.
| CRSR | MRK | |
|---|---|---|
Market Cap | $1.42B | $351.28B |
Volume | 1,160,938 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $14.35 | $156.43 |
52-Week Low | $4.58 | $82.49 |
Typical Hold Time | 25 Days | 98 Days |
Enterprise Value | $1.41B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corsair Gaming (CRSR) trades at $13.09, down 3.68% today but showing strong earnings momentum with three consecutive quarterly beats. The stock maintains a bullish technical signal with current price near pivot point support at $13. Recent Q2 2026 results exceeded expectations with EPS of $0.23 versus $0.07 estimate, driving positive sentiment from institutional investors including Canada Pension Plan's new position. The company continues product innovation with VOXARA microphone launch and strategic acquisitions like Trak Racer assets.
While valuation appears elevated with P/E of 42.23, improving profitability trends and raised 2026 guidance support upside potential. Key risks include competitive gaming peripherals market and inconsistent cash flow generation. Analyst consensus shows mixed sentiment with 36% buy ratings but average price target of $12.40 suggests limited near-term upside from current levels.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
